VRTX · Vertex Pharmaceuticals Incorporated

📣 What VRTX Says Is Next

• early 2027 · “Vertex is on track to share data from the interim analysis of the AMPLITUDE study in early 2027.”
  Company press release, Aug 3, 2026 · SEC filing
• second half of 2026 · “The AMPLITUDE study is on track to complete full enrollment in the second half of 2026.”
  Company press release, Aug 3, 2026 · SEC filing
• by the end of 2026 · Povetacicept: “Vertex is on track to complete enrollment in this study by the end of 2026.”
  Company press release, Aug 3, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Oct 2026 · Phase 1 · Upcoming Trial · A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation
  Registry primary completion date, not a results date
• Oct 2026 · Phase 3 · Active Trial · A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
  Registry primary completion date, not a results date
• Nov 2026 · Phase 1 · Recruiting · Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Part
  Registry primary completion date, not a results date
• Dec 2026 · N/A · Active Trial · Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Ki
  Registry primary completion date, not a results date
• Jan 2027 · Phase 3 · Active Trial · Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants
  Registry primary completion date, not a results date
• Jan 2027 · Phase 4 · Recruiting · Evaluation of Pain Treatment After Total Knee Arthroplasty
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not VRTX's own candidates): Pregabalin, Tacrolimus Extended-Release, Midazolam Hydrochloride, Itraconazole, Efavirenz.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VRTX holds $13.6B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

• No operating cash burn in latest filings

Recent financing filings on SEC EDGAR:

• Feb 13, 2025 · Shelf registration · S-3ASR

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VRTX files for a raise →

👥 Who Owns VRTX

Share count 253,460,924 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.